Targeted drug delivery to emphysematous lungs: Inhibition of MMPs by doxycycline loaded nanoparticles

Parasaram, Vaideesh; Nosoudi, Nasim; LeClair, Renée J.; Binks, Andrew P.; Vyavahare, Naren

doi:10.1016/j.pupt.2016.06.004

Cited by 15 publications

(22 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In short, results showed that the delivery of the drug to neutrophils in murine models of obstructive lung diseases was able to control neutrophil-inflammation and subsequent lung disease thereby highlighting the potential clinical utility of polymeric NPs for asthma and COPD ( Vij et al, 2016 ). In a study targeted to repair the ECM, researchers utilized BSA NPs encapsulated with DOX to regenerate the degraded elastic tissue for emphysema ( Parasaram et al, 2016 ). The NPs were optimized for their size (∼175 nm), surface properties (-60 mV), yield (∼34%), drug encapsulation efficiency (∼17%), and release properties (∼9.7% over 24 h and ∼14% over 48 h) ( Parasaram et al, 2016 ).…”

Section: Nanomaterials To Modulate the Lung Tissue Microenvironmentmentioning

confidence: 99%

“…In a study targeted to repair the ECM, researchers utilized BSA NPs encapsulated with DOX to regenerate the degraded elastic tissue for emphysema ( Parasaram et al, 2016 ). The NPs were optimized for their size (∼175 nm), surface properties (-60 mV), yield (∼34%), drug encapsulation efficiency (∼17%), and release properties (∼9.7% over 24 h and ∼14% over 48 h) ( Parasaram et al, 2016 ). Release kinetics of DOX from the BSA NPs led to significant inhibition of MMPs in the lung for up to 4 weeks in vivo utilizing Sprague Dawley rat models ( Parasaram et al, 2016 ).…”

Section: Nanomaterials To Modulate the Lung Tissue Microenvironmentmentioning

confidence: 99%

“…The NPs were optimized for their size (∼175 nm), surface properties (-60 mV), yield (∼34%), drug encapsulation efficiency (∼17%), and release properties (∼9.7% over 24 h and ∼14% over 48 h) ( Parasaram et al, 2016 ). Release kinetics of DOX from the BSA NPs led to significant inhibition of MMPs in the lung for up to 4 weeks in vivo utilizing Sprague Dawley rat models ( Parasaram et al, 2016 ). Regenerative nanotherapeutics such as the work by Parasaram et al (2016) could serve as first-line active-based treatments thereby greatly addressing an unmet medical need for COPD treatment.…”

Section: Nanomaterials To Modulate the Lung Tissue Microenvironmentmentioning

confidence: 99%

“…Release kinetics of DOX from the BSA NPs led to significant inhibition of MMPs in the lung for up to 4 weeks in vivo utilizing Sprague Dawley rat models ( Parasaram et al, 2016 ). Regenerative nanotherapeutics such as the work by Parasaram et al (2016) could serve as first-line active-based treatments thereby greatly addressing an unmet medical need for COPD treatment.…”

Section: Nanomaterials To Modulate the Lung Tissue Microenvironmentmentioning

confidence: 99%

See 3 more Smart Citations

Nanotherapeutics to Modulate the Compromised Micro-Environment for Lung Cancers and Chronic Obstructive Pulmonary Disease

Seshadri

Ramamurthi

2018

Front. Pharmacol.

View full text Add to dashboard Cite

The use of nanomaterials to modulate the tumor microenvironment has great potential to advance outcomes in patients with lung cancer. Nanomaterials can be used to prolong the delivery time of therapeutics enabling their specific targeting to tumors while minimizing and potentially eliminating cytotoxic effects. Using nanomaterials to deliver small-molecule inhibitors for oncogene targeted therapy and cancer immunotherapy while concurrently enabling regeneration of the extracellular matrix could enhance our therapeutic reach and improve outcomes for patients with non-small cell lung cancer (NSCLC) and chronic obstructive pulmonary disease (COPD). The objective of this review is to highlight the role nanomedicines play in improving and reversing adverse outcomes in the tumor microenvironment for advancing treatments for targeting both diseases.

show abstract

Section: Nanomaterials To Modulate the Lung Tissue Microenvironmentmentioning

confidence: 99%

Section: Nanomaterials To Modulate the Lung Tissue Microenvironmentmentioning

confidence: 99%

Section: Nanomaterials To Modulate the Lung Tissue Microenvironmentmentioning

confidence: 99%

Section: Nanomaterials To Modulate the Lung Tissue Microenvironmentmentioning

confidence: 99%

See 2 more Smart Citations

Nanotherapeutics to Modulate the Compromised Micro-Environment for Lung Cancers and Chronic Obstructive Pulmonary Disease

Seshadri

Ramamurthi

2018

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…For example, DOXY-PNPs were prepared to enhance its antibacterial activity against some types of bacteria [ 20 ] or to reduce its toxicity [ 21 ]. Meanwhile, as an antitumor agent, some types of DOXY nanoparticles were prepared to enhance its penetration into cancer cells [ 22 ], augment its anticancer activity [ 23 ] or improve drug delivery and efficacy [ 24 , 25 ] however, DOXY-PNPs were not designed before.…”

Section: Introductionmentioning

confidence: 99%

Synthesis and Antitumor Activity of Doxycycline Polymeric Nanoparticles: Effect on Tumor Apoptosis in Solid Ehrlich Carcinoma

et al. 2020

View full text Add to dashboard Cite

Objectives: The aim of this study was to prepare doxycycline polymeric nanoparticles (DOXY-PNPs) with hope to enhance its chemotherapeutic potential against solid Ehrlich carcinoma (SEC). Methods: Three DOXY-PNPs were formulated by nanoprecipitation method using hydroxypropyl methyl cellulose (HPMC) as a polymer. The prepared DOXY-PNPs were evaluated for the encapsulation efficiency (EE%), the drug loading capacity, particle size, zeta potential (ZP) and the in-vitro release for selection of the best formulation. PNP number 3 was selected for further biological testing based on the best pharmaceutical characters. PNP3 (5 and 10 mg/kg) was evaluated for the antitumor potential against SEC grown in female mice by measuring the tumor mass as well as the expression and immunohistochemical staining for the apoptosis markers; caspase 3 and BAX. Results: The biological study documented the greatest reduction in tumor mass in mice treated with PNP3. Importantly, treatment with 5 mg/kg of DOXY-PNPs produced a similar chemotherapeutic effect to that produced by 10 mg/kg of free DOXY. Further, a significant elevation in mRNA expression and immunostaining for caspase 3 and BAX was detected in mice group treated with DOXY-PNPs. Conclusions: The DOXY-PNPs showed greater antitumor potential against SEC grown in mice and greater values for Spearman’s correlation coefficients were detected when correlation with tumor mass or apoptosis markers was examined; this is in comparison to free DOXY. Hence, DOXY-PNPs should be tested in other tumor types to further determine the utility of the current technique in preparing chemotherapeutic agents and enhancing their properties.

show abstract

Inflammation‐modulating nanoparticles for pneumonia therapy

Muhammad

Zhai

Wang

et al. 2021

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

Pneumonia is a common but serious infectious disease, and is the sixth leading cause for death. The foreign pathogens such as viruses, fungi, and bacteria establish an inflammation response after interaction with lung, leading to the filling of bronchioles and alveoli with fluids. Although the pharmacotherapies have shown their great effectiveness to combat pathogens, advanced methods are under developing to treat complicated cases such as virus‐infection and lung inflammation or acute lung injury (ALI). The inflammation modulation nanoparticles (NPs) can effectively suppress immune cells and inhibit inflammatory molecules in the lung site, and thereby alleviate pneumonia and ALI. In this review, the pathological inflammatory microenvironments in pneumonia, which are instructive for the design of biomaterials therapy, are summarized. The focus is then paid to the inflammation‐modulating NPs that modulate the inflammatory cells, cytokines and chemokines, and microenvironments of pneumonia for better therapeutic effects. This article is categorized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Respiratory Disease

show abstract

Targeted drug delivery to emphysematous lungs: Inhibition of MMPs by doxycycline loaded nanoparticles

Abstract: Graphical Abstract

Cited by 15 publications

References 56 publications

Nanotherapeutics to Modulate the Compromised Micro-Environment for Lung Cancers and Chronic Obstructive Pulmonary Disease

Nanotherapeutics to Modulate the Compromised Micro-Environment for Lung Cancers and Chronic Obstructive Pulmonary Disease

Synthesis and Antitumor Activity of Doxycycline Polymeric Nanoparticles: Effect on Tumor Apoptosis in Solid Ehrlich Carcinoma

Inflammation‐modulating nanoparticles for pneumonia therapy

Contact Info

Product

Resources

About